Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?

European Journal of Health Economics

Volumn 16, Issue 4, 2015, Pages 341-345

  van de Vooren, Katelijne ^a   Curto, Alessandro ^a   Garattini, Livio ^a  

^a CESAV   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EUROPE; HEALTH CARE POLICY; HEPATITIS C; HUMAN;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; EUROPE; HEALTH POLICY; HEPATITIS C; HUMANS;

EID: 84940006397     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0653-x     Document Type: Editorial

References (23)

1. WHO. Health, health systems and economic crisis in Europe: impact and policy implications. http://www.euro.who.int/en/media-centre/events/events/2013/04/oslo-conference-on-health-systems-and-the-economic-crisis/documentation/working-documents/health,-health-systems-and-economic-crisis-in-europe-impact-and-policy-implications. Accessed 29 Oct 2014
2. Anderson, R.: Systematic reviews of economic evaluations: utility or futility? Health Econ. 19, 350–364 (2010)
3. European Centre for Disease Prevention and Control: Surveillance and prevention of hepatitis B and C in Europe. ECDC, Stockholm (2010)
4. Cornberg, M., Razavi, H.A., Alberti, A., et al.: A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Hepatitis C virus genotyping in chronic hepatitis C patients. Liver Int. 31(Suppl 2), 30–60 (2011)
5. Qattan I, Emery V. Hepatitis C virus genotyping in chronic hepatitis C patients. Eur. Sci. J. Nov. 8(27) (2012)
6. Gluud, C., Koretz, R., Gurusamy, K.: Hepatitis C: a new direction, but an old story? Lancet 383, 2122–2123 (2014)
7. Feeney, E.R., Chung, R.T.: Antiviral treatment of hepatitis C. BMJ 349, g3308 (2014)
8. WHO. Hepatitis C, Factsheet No 164. http://www.who.int/mediacentre/factsheets/fs164/en/ (2014). Accessed 29 Oct 2014
9. Liang, T.J., Ghany, M.G.: Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 368, 1907–1917 (2013)
10. EMA. Sovaldi: EPAR—product information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002798/human_med_001723.jsp&mid=WC0b01ac058001d124. Accessed 29 Oct 2014
11. AbbVie press release. European medicines agency validates marketing authorization applications for AbbVie’s investigational, all-oral, interferon-free therapy for the treatment of genotype 1 chronic hepatitis C http://abbvie.mediaroom.com/2014-06-17-European-Medicines-Agency-Validates-Marketing-Authorization-Applications-for-AbbVies-Investigational-All-Oral-Interferon-Free-Therapy-for-the-Treatment-of-Genotype-1-Chronic-Hepatitis-C Accessed 29 Oct 2014
12. De Pouvourville, G., Ulmann, P., Nixon, et al.: The diffusion of health economics knowledge in Europe. The EURONHEED (European network of health economic evaluation databases) project. Pharmacoeconomics 23, 113–120 (2005)
13. Cure, S., Bianic, F., Gavart, S., et al.: Cost-effectiveness of telaprevir in combination with PEGylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis c genotype 1 patients. J. Med. Econ. 17(1), 77–87 (2014)
14. Cammà, C., Petta, S., Cabibbo, G., et al.: Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. J. Hepatol. 59(4), 658–666 (2013)
15. Cure, S., Bianic, F., Gavart, S., et al.: Cost-effectiveness of telaprevir in combination with PEGylated interferon alpha and ribavirin in previously untreated chronic hepatitis c genotype 1 patients. J. Med. Econ. 17(1), 65–76 (2014)
16. Blázquez-Pérez, A., San Miguel, R., Mar, J.: Cost effectiveness analysis of triple therapy with protease inhibitors in treatment-naïve hepatitis c patients. Pharmacoeconomics 31(10), 919–931 (2013)
17. Cammà, C., Petta, S., Enea, M., et al.: Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis c. Hepatology 56(3), 850–860 (2012)
18. Elbasha, E.H., Chhatwal, J., Ferrante, S.A., et al.: Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis c virus genotype 1 infection in Portugal. Appl. Health Econ. Health Policy 11(1), 65–78 (2013)
19. NICE technology appraisals [TA253]. Boceprevir for the treatment of genotype 1 chronic hepatitis C. https://www.nice.org.uk/guidance/ta253 (2012). Accessed 29 Oct 2014
20. NICE technology appraisals [TA252]. Telaprevir for the treatment of genotype 1 chronic hepatitis C. http://www.nice.org.uk/guidance/ta252 (2012). Accessed 29 Oct 2014
21. Reuters. France uses tax to put pressure on hepatitis C drug prices. http://www.reuters.com/article/2014/09/30/us-france-deficit-gilead-idUSKCN0HP15N20140930 (2014). Accessed 29 Oct 2014
22. Garattini, L., Tediosi, F., Di Cintio, E., et al.: Gruppo di studio ARCA (AIDS resources and costs analysis). Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care 13, 733–741 (2001)
23. Garattini, L., Van de Vooren, K., Freemantle, N.: Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines. J. R. Soc. Med. 107, 4–5 (2014)